Compare Novavax Inc (NVAX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.61. Which is the better fit depends on your goals.
| NVAX | SPHD | |
|---|---|---|
Market Cap | $1.62B | — |
Sector | Health | — |
52-Week High | $11.19 | $53.55 |
52-Week Low | $6.22 | $46.96 |
Enterprise Value | $1.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SPHD trades at $51.96, down 0.65% on the day, with a technical outlook showing mixed signals—bullish oscillators but bearish moving averages. The ETF offers a high dividend yield, targeting income investors with low volatility exposure. Recent news highlights its role in retirement portfolios but notes potential yield traps without quality filters.
The outlook remains cautious due to valuation concerns and competition from peers like SCHD. Risks include underperformance in total returns and sensitivity to interest rate changes. Income-focused investors may find value, but growth-oriented holders should monitor fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
